// App-Quantinova.ai

SAT0356 : THE ROLE OF IL-36 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SPONDYLARTHROPATHY ASSOCIATED PATHOLOGY DUE TO ITS UPSTREAM INDUCTION OF IL-23/IL-17 PATHWAY CYTOKINES AND STROMAL ACTIVATION IN AN IN VITRO ENTHESITIS MODEL.

Researchers

Presenter

  • K. Sharif

Principal Investigators

  • C. Bridgewood

  • T. Russell

  • H. Rowe

  • Q. Zhou

  • A. S. Rao

  • A. Khan

  • R. Dunsmuir

  • D. Mcgonagle

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Genetic Disorder

Disease

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Intercellular adhesion molecule 1

  • Interleukin 17A

  • Interleukin 6

  • Interleukin-23

  • Interleukin-36

  • Interleukin-8

Drug/Treatment

  • Methotrexate

  • IL-23/IL-17

  • ICAM-1

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved